Alvotech disclosed its fourth‑quarter 2025 financial results on March 18 2026, reporting revenue of $173.2 million, a 7.28 % increase over the prior year’s $162.0 million. The company’s adjusted earnings per share for the quarter were –$0.37, missing the consensus estimate of –$0.05 by $0.32. The revenue beat was driven largely by licensing income and a modest uptick in commercial sales, while the earnings miss reflected higher operating costs and a negative product‑revenue margin of –37 % in the quarter, a result of timing of orders and planned facility upgrades.
Gross margin for the quarter stood at 66 %, slightly below the 63 % margin recorded in the same period a year earlier, reflecting investment in manufacturing capacity. Full‑year 2025 revenue reached $593 million, up 21 % YoY, and adjusted EBITDA climbed to $137 million, a 27 % increase from the $108.3 million reported in FY 2024. Management reaffirmed its 2026 outlook, projecting total revenue of $650‑$700 million and adjusted EBITDA of $180‑$220 million—figures that fall roughly 14 % below the consensus analyst forecast of $811.6 million for the year.
Regulatory headwinds remain a key concern. The company received Complete Response Letters for four U.S. biologics license applications in Q4 2025, linked to issues identified during the FDA’s July 2025 inspection of its Reykjavik facility. Chief Operating Officer Joseph E. McClellan explained that the FDA did not raise issues with the analytical, pharmacokinetic, or clinical efficacy and safety data in the applications, which were “considered complete.” The company is implementing a comprehensive quality‑improvement program and plans to resubmit the affected applications in Q2 2026, targeting decisions by year‑end 2026.
Management highlighted the company’s expanding commercial footprint and financial strength. Founder and Executive Chairman Róbert Wessman noted, “We now have five approved and on‑market biosimilars supported by our global partners which provide Alvotech with commercial reach into 90 countries worldwide. We have an industry leading pipeline of 30 biosimilars in development and continue adding to it at an accelerated pace.” He added, “During the year we further strengthened our financial position, raising close to $300 million from capital markets to support continued investment in our development programs and manufacturing platform. We broadened our investor base through the listing of shares on Nasdaq Stockholm, providing better access to Nordic and European investors.” Chief Financial Officer Linda Jónsdóttir said the fourth‑quarter performance “landed within our guidance,” driven primarily by licensing revenues.
Investors reacted with caution, weighing the company’s solid revenue growth and cash position against the regulatory uncertainties and a 2026 revenue guidance that falls short of analyst expectations. The guidance reflects management’s focus on maintaining profitability amid ongoing FDA compliance efforts and the need to balance investment in new product launches with cost control.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.